Synergy Healthcare Agreement

Byotrol PLC
14 November 2006



                                  BYOTROL PLC

                     AGREEMENT WITH SYNERGY HEALTHCARE PLC

The Directors of Byotrol plc (the 'Company') are pleased to announce that the
Company has entered into an agreement with Synergy Healthcare plc ('Synergy')
which will see Byotrol's anti-microbial technology deployed into the NHS and
independent healthcare sector in the UK and the rest of the world.

Synergy Healthcare plc is a leading provider of outsourced medical services to
the UK and the Netherlands, with an annualised turnover of over £130million and
has over 2500 employees.  Synergy has been providing sterile services in the UK
since 1996 and is the UK's largest provider of decontamination and sterile
services for surgical instruments. The Company operates fifteen facilities and
processing approximately 40 million instruments per annum.

The contract gives Synergy exclusive sales and distribution rights to Byotrol's
technology in the healthcare market. In addition Synergy will market, sell and
distribute Byotrol's Assure product range to the NHS and Byotrol's existing
healthcare customers.  In the UK, Synergy will assume responsibility for
supplying products containing Byotrol to Byotrol's existing healthcare users,
Sun Choice Europe Limited and DBM Holdings Ltd.

The agreement will give Synergy the use of Byotrol technology in significant
healthcare markets for licences, fees and options totalling £2.3 million
together with an advance royalty payment of £400,000.

The agreement commences immediately with the UK market and incorporates options
that will grant similar rights to Synergy for both USA, Europe and the rest of
the world and these are exercisable between February 2007 and February 2008.

In addition to fees and royalties, Synergy will be purchasing Byotrol
concentrates for use in manufacture of anti-microbial products.

The agreement with Synergy demonstrates Byotrol's strategy to deploy its
technology in partnership with leading businesses in its chosen markets.

According to Stephen Falder, Deputy Chairman of Byotrol plc:

'This agreement will see the rapid commercialisation of Byotrol technology in
the healthcare market and demonstrates our ability to licence the Company's
technology to a major organisation allowing us to gain a significant and rapid
penetration into one of our chosen key markets.

We continue to progress discussions with several major multinationals regarding
an increasing number of opportunities that have been recently identified in the
Company's other target markets of Food Processing and Industrial & Technical.'

                                    - more -

Dr Richard Steeves, Chief Executive of Synergy Healthcare, commented:

'The acquisition of the worldwide rights for Byotrol is a major strategic step
forward for Synergy. Byotrol is an ideal fit for Synergy and, coupled with
AirCleanse will greatly enhance our product offering in the atmospheric
decontamination market. This is an area of critical concern to the healthcare
market worldwide in order to counteract the ever-increasing threat of hospital
acquired infections.'

14 November 2006

Enquiries:

Byotrol plc                                        0161 277 9518

Stephen Falder
Deputy Chairman

David McRobbie
Chief Executive

Charles Stanley Securities                         020 7149 6457

Philip Davies


First City PR                                      0207 436 7486

Allan Piper


McCann Erickson PR                                 01625 822540

Jim Rothnie



Notes To Editors:

About Byotrol

Byotrol's assure range has been specifically developed for the NHS covering all
areas from acute care to care homes and comprises disinfectant sprays for use
across a wide range of settings, cleaning and sanitising wipes, and a hand
sanitising mousse. The Company's patented technology has been proven, through
extensive testing, to be effective in eradicating and controlling a wide range
of organisms such as MRSA, c.difficile and e-coli. Byotrol remains active after
it has dried, providing anti-microbial protection for extended periods after
application and is able therefore to tackle the practical problems of odours and
spoilage caused by microbe activity.

Byotrol is not toxic to humans and does not require any specialist equipment or
alteration to existing cleaning regimens to be effective. A further advantage of
Byotrol is also its ultra low alcohol content, compared to competing products,
which means it does not dry or irritate the skin when used as a hand sanitiser
as part of infection control procedures.

An independently supervised study carried out at Glasgow Royal Infirmary showed
that daily cleaning with Byotrol's patented biocide of the ward's high contact
surfaces (including door handles, tables, television handsets, patient contact
systems and bed rails), representing a small fraction of the total surfaces
within the ward, resulted in a significant reduction in the incidence of MRSA.

The cleaning regimen, which required no special equipment or extra resource, was
practised for 4 months and the incidence of MRSA was shown to have been reduced
by 75% against the pre-trial condition of the ward. During this phase there were
test periods with no incidence of MRSA.

The Company recently obtained CE Marking status approving Byotrol for sale in
medical and disinfectant products in Europe and approval from the US Environment
Protection Agency for Byotrol to be used as a disinfectant, sanitiser and anti-
microbial product in a broad number of market sectors.





                      This information is provided by RNS
            The company news service from the London Stock Exchange